IGC Pharma, Inc. IGC
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
IGC Pharma, Inc. (IGC) is a healthcare company listed in the US with a market value of about $21M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$8M, a net margin of -643.7%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -21% a year, a 5-year average ROIC of -81%.
About IGC Pharma
IGC Pharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $8M in 2015 to $1M in 2025, a decline of about 16.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 53% over three years (dilution for shareholders). It spends 288% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $1M | $1M | $911000 | $397000 | $898000 | $4M | $5M | $2M | $580372 | $6M |
| Net income | -$8M | -$7M | -$13M | -$12M | -$15M | -$9M | -$7M | -$4M | -$2M | -$2M | -$3M |
| Free cash flow | -$5M | -$5M | -$5M | -$7M | -$8M | -$12M | -$13M | -$3M | -$2M | -$2M | -$279887 |
| EPS (diluted) | $-0.08 | $-0.09 | $-0.22 | $-0.22 | $-0.30 | $-0.21 | $-0.19 | $-0.00 | $-0.00 | $-0.07 | $-0.17 |
| Net margin | -643.7% | -560.4% | -966.5% | -1263.0% | -3782.4% | -981.2% | -179.6% | -80.1% | -81.4% | -321.7% | -44.1% |
| ROIC | — | -113.3% | -127.8% | -75.2% | -63.0% | -25.8% | -25.3% | -10.9% | -22.2% | -20.8% | -16.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does IGC Pharma pay a dividend?
Not currently.
Is IGC Pharma a good stock to buy?
We do not give buy or sell advice. IGC Pharma scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.